TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Everest Medicines Ltd. ( (HK:1952) ) just unveiled an update.
Everest Medicines Ltd. successfully held its Annual General Meeting on June 27, 2025, where all proposed resolutions were approved by shareholders. Key resolutions included the re-election of executive directors, authorization for the board to fix directors’ remuneration, re-appointment of Ernst & Young as auditors, and granting of general mandates for share repurchase and issuance. The approval of performance target awards for key executives under the Pre-IPO ESOP was also confirmed, indicating strong shareholder support for the company’s strategic direction and leadership.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.32 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Ltd. is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in the fields of oncology, autoimmune disorders, cardio-renal diseases, and infectious diseases. The company operates primarily in the Asian market, aiming to address unmet medical needs with innovative therapies.
Average Trading Volume: 6,211,223
Technical Sentiment Signal: Buy
Current Market Cap: HK$18.09B
For detailed information about 1952 stock, go to TipRanks’ Stock Analysis page.